Consideration of adjusted ideal body weight dosing in BG-C9074 (B7-H4 – targeting ADC) from pharmacokinetics, efficacy and safety perspectives

Hugh Giovinazzo, PharmD, PhD

Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01

Elena Elimova, MD

A Phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors

Judith Raimbourg, MD, PhD